In Europe, Virbac acquired products from the endocrine, mastitis and sulphonamide franchises of Intervet/Schering-Plough Animal Health. The agreement does not affect the marketing of these products in other global markets.
In a second agreement with Virbac that has also closed successfully, Virbac acquired Prosolvin, a product from the fertility range, for worldwide use. That acquisition also satisfied a request by the South African Competition Commission in connection with Schering-Plough’s 2007 acquisition of Organon BioSciences N.V. Virbac has acquired these assets for an aggregate €28 million in cash.
By separate agreement announced in April, products from Intervet/Schering-Plough Animal Health’s parasiticide, swine E. coli vaccine, ruminant clostridia
vaccine, equine influenza vaccine, ruminant neonatal
vaccine, anti-inflammatory, companion animal/insulin and companion animal/euthanasia, and rabies vaccine franchises will be acquired by a subsidiary of Pfizer. The closing of that transaction is expected to take place later this year following receipt of necessary regulatory approvals. Related Website
â€¢ Schering Plough Subscribe here to the free Pig Progress newsletter